APA (7th ed.) Citation

Goodall, R. L., Meredith, S. K., Nunn, A. J., Bayissa, A., Bhatnagar, A. K., Bronson, G., . . . Zagd, C. (2022). Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): An open-label, multicentre, randomised, non-inferiority trial. The Lancet (British edition), 400(10366), 1858-1868. https://doi.org/10.1016/S0140-6736(22)02078-5

Chicago Style (17th ed.) Citation

Goodall, Ruth L., et al. "Evaluation of Two Short Standardised Regimens for the Treatment of Rifampicin-resistant Tuberculosis (STREAM Stage 2): An Open-label, Multicentre, Randomised, Non-inferiority Trial." The Lancet (British Edition) 400, no. 10366 (2022): 1858-1868. https://doi.org/10.1016/S0140-6736(22)02078-5.

MLA (9th ed.) Citation

Goodall, Ruth L., et al. "Evaluation of Two Short Standardised Regimens for the Treatment of Rifampicin-resistant Tuberculosis (STREAM Stage 2): An Open-label, Multicentre, Randomised, Non-inferiority Trial." The Lancet (British Edition), vol. 400, no. 10366, 2022, pp. 1858-1868, https://doi.org/10.1016/S0140-6736(22)02078-5.